Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systemic inflammation is a determinant of outcomes of CD40 agonist–based therapy in pancreatic cancer patients
Max M. Wattenberg, Veronica M. Herrera, Michael A. Giannone, et al.
JCI Insight (2021) Vol. 6, Iss. 5
Open Access | Times Cited: 24

Showing 24 citing articles:

Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance
Mara H. Sherman, Gregory L. Beatty
Annual Review of Pathology Mechanisms of Disease (2022) Vol. 18, Iss. 1, pp. 123-148
Open Access | Times Cited: 218
Hepatocytes coordinate immune evasion in cancer via release of serum amyloid A proteins
Meredith L. Stone, Jesse Lee, Jae W. Lee, et al.
Nature Immunology (2024) Vol. 25, Iss. 5, pp. 755-763
Closed Access | Times Cited: 17
Epithelial and stromal co-evolution and complicity in pancreatic cancer
Sunil R. Hingorani
Nature reviews. Cancer (2022) Vol. 23, Iss. 2, pp. 57-77
Open Access | Times Cited: 67
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors
Charlotte Lemech, Keith Dredge, Darryn Bampton, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 1, pp. e006136-e006136
Open Access | Times Cited: 17
Tumour‐associated neutrophils: Potential therapeutic targets in pancreatic cancer immunotherapy
Qihang Wu, Han Mao, Zhengting Jiang, et al.
Immunology (2024) Vol. 172, Iss. 3, pp. 343-361
Closed Access | Times Cited: 6
Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options
Chunye Zhang, Shuai Liu, Ming Yang
World Journal of Gastroenterology (2022) Vol. 28, Iss. 48, pp. 6827-6845
Open Access | Times Cited: 22
Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment
Nikolaos Vitorakis, Antonios N. Gargalionis, Kostas A. Papavassiliou, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2876-2876
Open Access | Times Cited: 4
Case Report: Combined PD-1 and tyrosine kinase blockade stabilizes refractory pancreatic cancer guided by the spatial structure of tumor immune microenvironment
Heqi Yang, Yuhang Ma, Chenyan Zhang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Serum Amyloid A Proteins and Their Impact on Metastasis and Immune Biology in Cancer
Jesse Lee, Gregory L. Beatty
Cancers (2021) Vol. 13, Iss. 13, pp. 3179-3179
Open Access | Times Cited: 22
Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Gregory L. Beatty, Devora Delman, Jiayi Yu, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 17, pp. 3514-3525
Open Access | Times Cited: 9
IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone
Richard E. Kast
Oncoscience (2024) Vol. 11, pp. 15-31
Open Access | Times Cited: 3
Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles
Huan Yan, Guibin Lin, Zhanyan Liu, et al.
Acta Biomaterialia (2023) Vol. 161, pp. 213-225
Closed Access | Times Cited: 8
A Review of the Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Nonhematologic Malignancies
Defne Cigdem Koc, Ion Bogdan Mănescu, Măriuca Mănescu, et al.
Diagnostics (2024) Vol. 14, Iss. 18, pp. 2057-2057
Open Access | Times Cited: 1
Updates in Immunotherapy for Pancreatic Cancer
Robert C. Chick, Timothy M. Pawlik
Journal of Clinical Medicine (2024) Vol. 13, Iss. 21, pp. 6419-6419
Open Access | Times Cited: 1
Exogenous or in situ vaccination to trigger clinical responses in pancreatic cancer
Gregory L. Beatty, Elizabeth M. Jaffee
Carcinogenesis (2024) Vol. 45, Iss. 11, pp. 826-835
Closed Access | Times Cited: 1
T Cell Exhaustion and Activation Markers in Pancreatic Cancer: A Systematic Review
Smriti Mishra, Gaurang Telang, Darpan Bennur, et al.
Journal of Gastrointestinal Cancer (2023) Vol. 55, Iss. 1, pp. 77-95
Closed Access | Times Cited: 3
TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy
Meredith L. Stone, Jesse Lee, Veronica M. Herrera, et al.
JCI Insight (2021) Vol. 6, Iss. 14
Open Access | Times Cited: 7
Clinical trial-identified inflammatory biomarkers in breast and pancreatic cancers
Jing Peng, Supradeep S. Madduri, Angela D. Clontz, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 2
Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer
David Digomann, Max Heiduk, Charlotte Reiche, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 1
Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B
Emre Basar, Henry Mead, Bennett O. V. Shum, et al.
Pharmaceutics (2024) Vol. 16, Iss. 9, pp. 1207-1207
Open Access
A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice
Aman Mebrahtu, Anders Olsson, Rosanne Veerman, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access
Enhanced safety and efficacy profile of CD40 antibody upon encapsulation in pHe-triggered membrane-adhesive nanoliposomes
Salma Althobaiti, Prahlad Parajuli, Duy Luong, et al.
Nanomedicine (2024) Vol. 20, Iss. 2, pp. 155-166
Closed Access
Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection
Xiaoqin Ji, Bin Zhou, Wei Ding, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 2
Chemokine Receptor 2 Targeted PET/CT Imaging Distant Metastases in Pancreatic Ductal Adenocarcinoma
Xiaohui Zhang, Lisa Detering, Gyu Seong Heo, et al.
ACS Pharmacology & Translational Science (2023)
Closed Access
Page 1

Scroll to top